ShamMailankodyMD

PubMed

• Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
  Anna J Howard, Isabel Concepcion, Alice X Wang, Issam S Hamadeh, Malin L Hultcrantz, Sham Mailankody, Carlyn Rose Tan, Neha Korde, Alexander M Lesokhin, Hani Hassoun, ...> ;Blood Advances. 2024 Apr 12
• Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
  Issam S Hamadeh, Tala Shekarkhand, Colin Joseph Rueda, Ross S Firestone, Alice X Wang, Neha Korde, Malin L Hultcrantz, Alexander M Lesokhin, Sham Mailankody, Hani Hass...> ;Blood Advances. 2024 Apr 10
• 1 citations
  CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
  Ross S Firestone, Devin McAvoy, Tala Shekarkhand, Edith Serrano, Issam Hamadeh, Alice Wang, Menglei Zhu, Wei Ge Qin, Dhwani Patel, Carlyn R Tan, Malin Hultcrantz, Sham...> ;Blood Advances. 2024 Apr 9
• Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
  Lesokhin, A., Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B., Nishimura, N., Farzana, T., Rueda, C., Chung, D., Landau, H., Lahoud, O., Scordo, M., ...> ;Research Square. 2024 Feb 7
• 3 citations
  Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
  Urvi A Shah, Erin Moshier, Andriy Derkach, Yuanhui Huang, Sham Mailankody, Carlyn R Tan, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Hani Hassoun, Santiago Thibaud...> ;Blood Advances. 2024 Jan 9
• 1 citations
  Current use of CAR T cells to treat multiple myeloma.
  Firestone, R., Mailankody, S.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
• 2 citations
  Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
  Francesco Maura, Eileen M Boyle, David Coffey, Kylee Maclachlan, Dylan Gagler, Benjamin Diamond, Hussein Ghamlouch, Patrick Blaney, Bachisio Ziccheddu, Anthony Cirrinc...> ;Nature Cancer. 2023 Dec 1
• Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells.
  Xiaoli Mi, Alex Penson, Omar Abdel-Wahab, Sham Mailankody> ;The New England Journal of Medicine. 2023 Oct 12
• 2 citations
  CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review.
  Norah Layla Sadek, Bruno Almeida Costa, Karthik Nath, Sham Mailankody> ;Clinical Pharmacology and Therapeutics. 2023 Dec 1
• Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Blood Cancer Journal. 2023 Jul 25
• 2 citations
  The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.
  Karthik Nath, Sham Mailankody, Saad Z Usmani> ;Hematology/oncology Clinics of North America. 2023 Dec 1
• 7 citations
  Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Dec 1
• 1 citations
  Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort ...
  Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith, Malin Hultcra...> ;Eclinicalmedicine. 2023 Mar 1
• 1 citations
  Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Research Square. 2023 Feb 24
• Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations.
  Allison Lipitz-Snyderman, Susan Chimonas, Sham Mailankody, Michelle Kim, Nicholas Silva, Anuja Kriplani, Leonard B Saltz, Smita Sihag, Carlyn Rose Tan, Maria Widmar, M...> ;Cancer Medicine. 2023 Apr 1
• 8 citations
  GPRC5D as a novel immunotherapeutic target in multiple myeloma.
  Karthik Nath, Bruno A Costa, Sham Mailankody> ;Nature Reviews. Clinical Oncology. 2023 May 1
• 58 citations
  Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Feb 1
• 15 citations
  Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
  Taxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, David Siegel, Krina Patel, Sham Mailankody, Myo Htut, Nina Shah, Sandy W Wong, Surbhi Sidana, Andrew J Cowan, Melis...> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 5 citations
  Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
  Urvi A Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M Lesokhi...> ;Blood Cancer Journal. 2023 Jan 12
• 1 citations
  Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
  Matthew J Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P Salvatore, Insara Jaffer-Sathick, Adriana C Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A Sha...> ;American Journal of Hematology. 2023 Mar 1
• 2 citations
  Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained ...
  Kenneth Cornetta, Jing Yao, Kimberley House, Lisa Duffy, Prasad S Adusumilli, Rachel Beyer, Claire Booth, Malcolm Brenner, Kevin Curran, Bambi Grilley, Helen Heslop, C...> ;Molecular Therapy. 2023 Mar 1
• 22 citations
  Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
  Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T Melnekoff, Yogita Ghodke-Puranik, Gunjan L Shah, Alexander Lesokhin, Serg...> ;Blood. 2023 Feb 16
• 7 citations
  Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer.
  Angela K Green, Sara M Tabatabai, Carol Aghajanian, Ola Landgren, Gregory J Riely, Paul Sabbatini, Peter B Bach, Colin B Begg, Allison Lipitz-Snyderman, Sham Mailankody> ;JAMA Oncology. 2022 Dec 1
• A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
  Karthik Nath, Tala Shekarkhand, Meghan Salcedo, Andriy Derkach, Siobhan Rueda, Aisara Chansakul, Malin Hulcrantz, Neha Korde, Urvi A Shah, Carlyn Tan, David J Chung, O...> ;Leukemia & Lymphoma. 2022 Dec 1
• 85 citations
  GPRC5D-Targeted CAR T Cells for Myeloma.
  Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte, Elizabeth J Carstens, Douglas Russo, Romany Auclair, Lisa Fitzgerald, Briana Cadzin, Xi...> ;The New England Journal of Medicine. 2022 Sep 29
• Join now to see all

Journal Articles

• Addendum: Low-Value Approvals and High Prices Might Incentivize Ineffective Drug Development  
  Sham Mailankody, MD, Nature